Abstract：
BACKGROUND: The study aims to determine the survival and recurrence rates of pilonidal sinus disease (PSD) carcinoma.
METHODS: The data were collected retrospectively by searching the worldwide literature for all reports of carcinoma developing on the background of PSD. The results were presented using Kaplan-Meier curves.
RESULTS: Between 1900 and 2022, 140 cases of PSD carcinoma were published in 103 papers, with follow-up data available in 111 cases. Squamous cell carcinoma constituted 94.6% of the cases (n = 105). The disease-specific survival rate was 61.7% for 3 years, 59.8% for 5 years, and 53.2% for 10 years. There was a significant survival difference between stages: 80.0% in stages I and II, 70.8% in stage III, and 47.8% in stage IV (p = 0.01). The 5-year survival in G1-tumors was better than G2 and G3-tumors at 70.5% and 32.0%, respectively (p = 0.002). Recurrence occurred in 46.6% of the patients. The time-to-recurrence in patients treated with curative intention averaged 15.1 months (1-132 months). Local, regional, and distant recurrence was observed in 75.6%, 33.3%, and 28.9% of the recurrent tumors, respectively.
CONCLUSIONS: Pilonidal sinus carcinoma has a worse prognosis than primary cutaneous squamous cell carcinoma. Poor prognostic factors include advanced-stage disease and poor differentiation.
METHODS: The data were collected retrospectively by searching the worldwide literature for all reports of carcinoma developing on the background of PSD. The results were presented using Kaplan-Meier curves.
RESULTS: Between 1900 and 2022, 140 cases of PSD carcinoma were published in 103 papers, with follow-up data available in 111 cases. Squamous cell carcinoma constituted 94.6% of the cases (n = 105). The disease-specific survival rate was 61.7% for 3 years, 59.8% for 5 years, and 53.2% for 10 years. There was a significant survival difference between stages: 80.0% in stages I and II, 70.8% in stage III, and 47.8% in stage IV (p = 0.01). The 5-year survival in G1-tumors was better than G2 and G3-tumors at 70.5% and 32.0%, respectively (p = 0.002). Recurrence occurred in 46.6% of the patients. The time-to-recurrence in patients treated with curative intention averaged 15.1 months (1-132 months). Local, regional, and distant recurrence was observed in 75.6%, 33.3%, and 28.9% of the recurrent tumors, respectively.
CONCLUSIONS: Pilonidal sinus carcinoma has a worse prognosis than primary cutaneous squamous cell carcinoma. Poor prognostic factors include advanced-stage disease and poor differentiation.
摘要：
背景：该研究旨在确定藏毛窦癌（PSD）的生存率和复发率。
方法：通过检索世界范围内所有以PSD为背景的癌症发展的文献，对数据进行回顾性收集。使用Kaplan-Meier曲线呈现结果。
结果：在1900年至2022年之间，140例PSD癌发表在103篇论文中，111例病例的随访数据。鳞状细胞癌占病例的94.6％（n=105）。3年的疾病特异性生存率为61.7%,5年内59.8%，和53.2%的10年。分期之间有显著的生存差异:Ⅰ期和Ⅱ期80.0%,第三阶段为70.8%，第四阶段为47.8%(p=0.01)。G1肿瘤的5年生存率优于G2和G3肿瘤，分别为70.5%和32.0%。分别(p=0.002)。46.6%的患者复发。治愈意向治疗患者的复发时间平均为15.1个月（1-132个月）。当地,区域,远处复发占75.6%,33.3%,28.9%的复发性肿瘤，分别。
结论：毛发窦癌的预后比原发性皮肤鳞状细胞癌的预后差。预后不良的因素包括疾病晚期和分化差。
方法：通过检索世界范围内所有以PSD为背景的癌症发展的文献，对数据进行回顾性收集。使用Kaplan-Meier曲线呈现结果。
结果：在1900年至2022年之间，140例PSD癌发表在103篇论文中，111例病例的随访数据。鳞状细胞癌占病例的94.6％（n=105）。3年的疾病特异性生存率为61.7%,5年内59.8%，和53.2%的10年。分期之间有显著的生存差异:Ⅰ期和Ⅱ期80.0%,第三阶段为70.8%，第四阶段为47.8%(p=0.01)。G1肿瘤的5年生存率优于G2和G3肿瘤，分别为70.5%和32.0%。分别(p=0.002)。46.6%的患者复发。治愈意向治疗患者的复发时间平均为15.1个月（1-132个月）。当地,区域,远处复发占75.6%,33.3%,28.9%的复发性肿瘤，分别。
结论：毛发窦癌的预后比原发性皮肤鳞状细胞癌的预后差。预后不良的因素包括疾病晚期和分化差。
